Wren laboratories announces advanced NETest 2.0 for neuroendocrine tumour diagnostics
Wren Laboratories has officially discontinued their original NETest 1.0 in favour of an AI-enhanced successor. The new liquid biopsy diagnostic offers improved sensitivity and accuracy for monitoring neuroendocrine tumours through an optimised 51-gene mRNA expression algorithm.
Refined molecular signature enhances clinical utility NETest 2.0 delivers impressive performance metrics with >95% sensitivity for NET detection and >90% accuracy in identifying progressive disease. The integrated PPQ Score predicts patient response to peptide receptor radionuclide therapy (PRRT) with 98% positive predictive value and 93% negative predictive value. This non-invasive diagnostic tool has undergone rigorous validation across diverse patient cohorts spanning multiple continents, establishing its reliability in varied clinical settings.
Expert perspectives on implementation
Dr Abdel Halim, PharmD, PhD, CEO/CSO of Wren Laboratories, noted: “NETest 2.0 represents a major leap forward in patient surveillance and therapeutic decision-making for individuals with NETs.” Laboratory Director Dr Mark Kidd highlighted the advancement’s practical significance: “With NETest 2.0, we’ve significantly enhanced diagnostic precision, allowing for improved patient surveillance and better treatment outcomes.”
Dr Vikas Prasad, nuclear medicine expert at Washington University School of Medicine, added: “NET patients, specifically being treated with radiopharmaceutical therapies and under active surveillance may profit from state-of-the-art biomarkers like NETest2.0.”
The test is available under CLIA, CAP, and NYSDOH CLEP certification for patients, investigators and biopharmaceutical research applications.
For more information, visit: https://wrenlaboratories.com/biopharma-research
Digital issue: Please click here for more information
